Atrial natriuretic peptide: Old but new therapeutic in cardiovascular diseases

Tomoko Ichiki, John C. Burnett

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


With the discovery of atrial natriuretic peptide (ANP), the heart as an endocrine organ was established. Basic science revealed that ANP, through the particulate guanylyl cyclase A receptor and cGMP, plays a fundamental role in cardiorenal biology. This work has led to the development of ANP as a therapeutic, especially in heart failure (HF). Human genomics has strengthened our understanding of ANP, revealing specific ANP gene variants that may be associated with biological dysfunction, but also may mediate protective properties, including in metabolic syndrome. Advances in understanding the processing and degradation of ANP molecular forms have resulted in therapeutic breakthroughs, especially inhibition of ANP degradation by neprilysin inhibitors. Although ANP is administered intravenously for acute HF, a novel therapeutic strategy is its chronic delivery by subcutaneous injection. An innovative therapeutic development is engineering to develop ANP-based peptides for chronic use. These interconnected topics of ANP biology and therapeutics will be reviewed in detail.

Original languageEnglish (US)
Pages (from-to)913-919
Number of pages7
JournalCirculation Journal
Issue number7
StatePublished - 2017


  • Atrial natriuretic peptide
  • Cardiorenal biology
  • cGMP

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Atrial natriuretic peptide: Old but new therapeutic in cardiovascular diseases'. Together they form a unique fingerprint.

Cite this